Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gubra ASFRA:PI3 -1.92%68 Net Cash per Share is €5.32 as of Jun. 2026, which is 100% below its 10-year median of 8.09. GuruFocus rates FRA:PI3 with a GF Score™ of 68/100 and a GF Value™ of €26.08 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 757 Biotechnology companies, Gubra AS ranks worse than 59.18% on this metric.
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Gubra AS Net Cash per Share Related Terms
Gubra AS Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Gubra AS's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PI3 vs VRTX, REGN, RVMD: Net Cash per Share Comparison
For the Biotechnology subindustry, Gubra AS's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gubra AS Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gubra AS's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Gubra AS's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Gubra AS's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gubra AS (FRA:PI3) has a Net Cash per Share of €5.32 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Gubra AS and its competitors. This is 34% below median its historical median of 8.09. Over the past decade, Gubra AS's Net Cash per Share has ranged from 3.96 to 39.10. According to the industry distribution chart, Gubra AS ranks #448 out of 757 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Gubra AS's Net Cash per Share too high?
Gubra AS's current Net Cash per Share of €5.32 is 34% below median its 10-year median of 8.09. Over the past 10 years, this metric has ranged from a low of 3.96 to a high of 39.10. Based on the distribution chart, Gubra AS ranks #448 out of 757 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Gubra AS has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Gubra AS's Net Cash per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gubra AS ranks #448 out of 757 companies for Net Cash per Share. This places Gubra AS in the lower half of its industry. The industry median Net Cash per Share is 5.17. Historically, Gubra AS's own Net Cash per Share has ranged from 3.96 to 39.10 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.17, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Gubra AS and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gubra AS's current Net Cash per Share is €5.32, which is 34% below median its own 10-year median of 8.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gubra AS stock overvalued right now?
Based on GuruFocus' analysis, Gubra AS (FRA:PI3) is currently considered Possible Value Trap. The stock's GF Value™ is €26.08, compared to a current price of €51.00 — trading 95.6% above its estimated fair value. The current Net Cash per Share is €5.32, which is 34% below median its 10-year median of 8.09. Gubra AS's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Gubra AS (FRA:PI3), the current Net Cash per Share is €5.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gubra AS (FRA:PI3) Overvalued in 2026?
Based on GuruFocus' analysis, Gubra AS stock appears to be overvalued.
The current stock price of €51.00 is trading 95.6% above its estimated GF Value™ of €26.08.
GuruFocus considers Gubra AS to be Possible Value Trap.
Key valuation signals for FRA:PI3:
Net Cash per Share: €5.32 (34% below median its 10-year median of 8.09)
GF Value™: €26.08 vs. price of €51.00 (95.6% above fair value)
No single metric tells the full story. See the FRA:PI3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has two segments: Pre-clinical contract research (CRO), which derives maximum revenue and Biotech Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.
68GF Score
Get the complete analysis for FRA:PI3
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PI3 has been successfully added to your 
